Polycystic Kidney Disease – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 8 PAGES: 46

More Info
									 Polycystic Kidney Disease – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1845IDB
                                                                                             Publication Date: March 2012




Polycystic Kidney Disease – Pipeline Review, H1 2012                                        GMDHC1845IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(1)
Polycystic Kidney Disease – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Polycystic Kidney Disease Overview .................................................................................................................................................. 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Polycystic Kidney Disease.................................................................................................. 7
Polycystic Kidney Disease Therapeutics under Development by Companies .................................................................................... 9
Polycystic Kidney Disease Therapeutics under Investigation by Universities/Institutes ................................................................... 10
Late Stage Products ......................................................................................................................................................................... 11
    Comparative Analysis .................................................................................................................................................................. 11
Mid Clinical Stage Products.............................................................................................................................................................. 12
    Comparative Analysis .................................................................................................................................................................. 12
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 13
    Comparative Analysis .................................................................................................................................................................. 13
Polycystic Kidney Disease Therapeutics – Products under Development by Companies ................................................................ 14
Polycystic Kidney Disease Therapeutics – Products under Investigation by Universities/Institutes ................................................. 15
Companies Involved in Polycystic Kidney Disease Therapeutics Development ............................................................................... 16
    Pfizer Inc...................................................................................................................................................................................... 16
    Indus Biotech Private Limited ...................................................................................................................................................... 17
    Napo Pharmaceuticals, Inc. ......................................................................................................................................................... 18
    Kemin Industries, Inc. .................................................................................................................................................................. 19
    Pharnext SAS .............................................................................................................................................................................. 20
Polycystic Kidney Disease – Therapeutics Assessment .................................................................................................................. 21
    Assessment by Monotherapy Products ....................................................................................................................................... 21
    Assessment by Combination Products ........................................................................................................................................ 22
    Assessment by Route of Administration ...................................................................................................................................... 23
    Assessment by Molecule Type .................................................................................................................................................... 25
Drug Profiles..................................................................................................................................................................................... 27
    Bosutinib - Drug Profile ................................................................................................................................................................ 27
         Product Description................................................................................................................................................................. 27
         Mechanism of Action ............................................................................................................................................................... 27
         R&D Progress ......................................................................................................................................................................... 27
    AM1101 - Drug Profile ................................................................................................................................................................. 29
         Product Description................................................................................................................................................................. 29
         Mechanism of Action ............................................................................................................................................................... 29
         R&D Progress ......................................................................................................................................................................... 29
    INDUS815B - Drug Profile ........................................................................................................................................................... 30
         Product Description................................................................................................................................................................. 30
         Mechanism of Action ............................................................................................................................................................... 30
         R&D Progress ......................................................................................................................................................................... 30



Polycystic Kidney Disease – Pipeline Review, H1 2012                                                                                            GMDHC1845IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Polycystic Kidney Disease – Pipeline Review, H1 2012




    Samsca - Drug Profile ................................................................................................................................................................. 31
         Product Description................................................................................................................................................................. 31
         Mechanism of Action ............................................................................................................................................................... 31
         R&D Progress ......................................................................................................................................................................... 31
    Rapamycin - Drug Profile ............................................................................................................................................................ 33
         Product Description................................................................................................................................................................. 33
         Mechanism of Action ............................................................................................................................................................... 33
         R&D Progress .............................................................................................
								
To top